期刊
ACS CHEMICAL NEUROSCIENCE
卷 9, 期 7, 页码 1693-1701出版社
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.8b00067
关键词
Alzheimer's disease; human; chronic; electrophysiology; A beta oligomers
资金
- National Institute of Health [R01NS050452]
- Department of the Army [W81XWH1410162]
- U.S. Department of Defense (DOD) [W81XWH1410162] Funding Source: U.S. Department of Defense (DOD)
Alzheimer's disease (AD) is characterized by slow, progressive neurodegeneration leading to severe neurological impairment, but current drug development efforts are limited by the lack of robust, human-based disease models. Amyloid-beta (A beta) is known to play an integral role in AD progression as it has been shown to interfere with neurological function. However, studies into AD pathology commonly apply A beta to neurons for short durations at nonphysiological concentrations to induce an exaggerated dysfunctional phenotype. Such methods are unlikely to elucidate early stage disease dysfunction, when treatment is still possible, since damage to neurons by these high concentrations is extensive. In this study, we investigated chronic, pathologically relevant A beta oligomer concentrations to induce an electrophysiological phenotype that is more representative of early AD progression compared to an acute high-dose application in human cortical neurons. The high, acute oligomer dose resulted in severe neuronal toxicity as well as upregulation of tau and phosphorylated tau. Chronic, low-dose treatment produced significant functional impairment without increased cell death or accumulation of tau protein. This in vitro phenotype more closely mirrors the status of early stage neural decline in AD pathology and could provide a valuable tool to further understanding of early stage AD pathophysiology and for screening potential therapeutic compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据